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First clinical trial of nitinol self-expanding
everolimus-eluting stent implantation for
peripheral arterial occlusive disease
Johannes Lammer, MD,a Marc Bosiers, MD,b Thomas Zeller, MD,c Martin Schillinger, MD,d Els Boone,
MSc,e Margo J. Zaugg, BSN,e Patrick Verta, MD,e Lei Peng, MSc,e Xingyu Gao, MSc,e and
Lewis B. Schwartz, MD,e Vienna, Austria; Dendermonde, Belgium; Bad Krozingen, Germany; and Abbott,
Park, Ill
Background: A novel self-expanding drug-eluting stent was designed to slowly release everolimus to prevent restenosis
following peripheral arterial intervention. The purpose of the first-in-human Superficial Femoral Artery Treatment with
Drug-Eluting Stents (STRIDES) trial was to evaluate the safety and efficacy of this device for the treatment of
symptomatic superficial femoral and proximal popliteal arterial occlusive disease.
Methods and Results: One hundred four patients were enrolled at 11 European investigative centers in a prospective,
nonrandomized, single-arm trial. The patients had severe symptomatic vascular disease, including a significant propor-
tion of patients with critical limb ischemia (17%), diabetes (39%), and single-vessel outflow (26%). Themean lesion length
was 9.0  4.3 cm. Ninety-nine percent of patients were available for 12-month follow-up, including duplex imaging in
90% and arteriography in 83%. Clinical improvement, defined as a sustained decrease in Rutherford-Becker clinical
category, was achieved in 80% of patients. Primary patency (freedom from >50% in-stent restenosis) was 94  2.3% and
68  4.6% at 6 and 12 months, respectively. Plain radiographic examination of 122 implanted devices at 12 months
revealed no evidence for stent fracture.
Conclusions: The everolimus-eluting self-expanding nitinol stent can be successfully implanted in patients with severe
peripheral arterial disease with favorable outcomes and clinical improvements observed in the majority of patients.
(J Vasc Surg 2011;54:394-401.)
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tEndovascular recanalization has become the preferred
method of treatment for many patients with symptomatic
femoropopliteal occlusive disease. It is the recommended
approach for all ischemic patients with segmental disease
15 cm and for selected patients with more diffuse disease
at prohibitive risk for open surgery.1
Despite its widespread popularity and applicability,
however, the durability of endovascular intervention re-
mains poor. Restenosis complicates up to 50% of proce-
dures during the first year leading to high rates of therapeu-
tic failure and reintervention.2-5
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394Given the significant impact that drug-eluting stents
DES) have had in reducing restenosis rates in the coronary
irculation,6 several methods of intravascular stent-based
ocal drug delivery have been developed for peripheral
nterventions.7-10 In this study, an everolimus-eluting pe-
ipheral stent system was designed with a relatively high
rug load (225 g/cm2) and long elution profile (about
0% released during the first 3 months). The purpose of the
rst-in-human Superficial Femoral Artery Treatment with
rug-Eluting Stents (STRIDES) trial was to evaluate the
afety and efficacy of this novel everolimus-eluting stent
ystem for the treatment of symptomatic superficial femoral
nd proximal popliteal arterial occlusive disease.
ETHODS
Study design. The STRIDES trial was a prospective,
onrandomized, single-arm, multicenter clinical study de-
igned to evaluate the safety and performance of an everoli-
us-eluting self-expanding stent system for the treatment
f atherosclerotic peripheral artery disease (PAD). The
tudy was designed to enroll approximately 100 patients
ith chronic PAD in Rutherford-Becker clinical categories
to 5 (moderate to severe intermittent claudication, isch-
mic rest pain, or minor tissue loss) due to atherosclerotic
e novo or restenotic occlusive lesions of the superficial
emoral or proximal popliteal artery 3 and 17 cm in
ength. It was conducted in accordance with the Interna-
ional Conference on Harmonization Guidelines-Good
linical Practices, Declaration of Helsinki, ISO 14155-1,
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Volume 54, Number 2 Lammer et al 395ISO 14155-2 and Ethics Committee requirements, and all
patients gave written informed consent for participation.
The trial was registered at http://www.clinicaltrials.gov
with the identifier NCT00475566.
Patients were eligible for enrollment in the STRIDES
trial if they were suffering from symptomatic PAD due to a
single de novo or restenotic lesion of the superficial femoral
artery (SFA) or proximal popliteal artery located between
the point 1 cm distal to the femoral bifurcation and the
point 3 cm proximal to the proximal margin of the inter-
condylar fossa of the femur. Lesions with 50% diameter
stenosis were considered eligible for the trial when their
length was 3 cm and 17 cm, and they arose in target
vessels with diameters 4.3 mm and 7.3 mm. Patients
with significant inflow stenosis were eligible for inclusion if
the stenosis had been successfully treated without compli-
cation. Patients were required to have a patent popliteal
artery as well as at least one patent tibial artery that provided
in-line circulation to the lower leg and foot. For patients
with bilateral SFA lesions, the lesion referable to the limb
with the highest Rutherford-Becker clinical category was
treated.
Key exclusion criteria included prior placement of an
intravascular stent in the SFA, prior bypass grafting in the
extremity, the presence of major tissue loss (Rutherford-
Becker clinical category 6), blind popliteal outflow, the
presence of an active immunosuppressive disorder, active
pharmacologic treatment with known inducers of CYP3A,
prior or planned solid organ transplantation, severe hepatic
insufficiency, or renal insufficiency defined by a serum
creatinine 2.5 mg/dL.
Drug-eluting stent system. The everolimus-eluting
peripheral stent was comprised of three components: the
Dynalink nitinol self-expanding stent (Abbott Laborato-
ries, Abbott Park, Ill), the antiproliferative drug everoli-
mus, and an ethylene vinyl alcohol (EVAL, Kuraray Co,
Ltd, Tokyo, Japan) copolymer.
The Dynalink .035 peripheral self-expanding stent is
constructed of binary nickel-titanium, which is superelastic
at body temperature. The 0.008-inch strut thickness design
is based on a series of sinusoidal rings that are connected at
six locations around the circumference such that the con-
nections are aligned along the length of the stent and
positioned 60 degrees from each other. The Dynalink and
Absolute stents (Abbott) are identical, except that the
Absolute stent contains radiopaque markers at its ends to
facilitate deployment. TheDynalink/Absolute stent system
has been shown to be safe and efficacious in several single-
arm and randomized trials of endovascular therapy for
PAD.4,11,12
The antiproliferative drug, everolimus, is a therapeutic
agent originally developed for the prevention of organ
transplant rejection but is also effective at inhibiting the
growth of certain solid tumors (Certican and Afinitor;
Novartis Pharmaceuticals Corporation, Basel, Switzer-
land).13,14 It effectively inhibits experimental vascular
smooth muscle cell proliferation and enhances vascular
remodeling in animal models.15,16 Lastly, everolimus has ceen shown to be safe and effective as the drug component
f coronary DES.17
The release of everolimus from the peripheral
verolimus-eluting stent is controlled by an ethylene vinyl
lcohol (EVAL) copolymer. EVAL is a semicrystalline poly-
er with a glass transition temperature of 55°C and melt-
ng point of 180°C. The chemical backbone is a C–C bond
nd the pendant group is –OH; neither contains hydrolyti-
ally or oxidatively labile chemical bonds. Owing to their
iocompatibility, EVAL polymers are ubiquitous in medi-
ine. They have been used as hemodialysis and apheresis
embranes18 and, more recently, have been formulated
ith dimethyl sulfoxide for use as embolic treatment for
ntracerebral aneurysms and arteriovenous malforma-
ions.19 The STRIDES study is notable in that it represents
he first clinical experience with EVAL as a polymer for
ntravascular drug elution. Other everolimus-eluting
tents, most notable the Xience V device (Abbott), employ
fluorinated polymer drug carrier, poly(vinylidene fluo-
ide-co-hexafluoropropylene) (PVDF-HFP) to control
rug release.
This combination of the Dynalink nitinol self-expand-
ng stent, the antiproliferative drug everolimus, and an
thylene vinyl alcohol (EVAL) copolymer has been referred
o as the “Dynalink-E” stent (Fig 1). The total drug load is
25g/cm2 stent surface area, a higher dose than coronary
irolimus-eluting (140 g/cm2) or everolimus-eluting
tents (100 g/cm2).20 The elution profile is prolonged as
ell with approximately 80% of the drug being released
lowly over the first 90 days, as opposed to 30 days in
ystems designed for use in the coronary arteries.21
Treatment strategy and follow-up procedures.
rior to the stenting procedure, patients received one of
wo antiplatelet regimens: (1) aspirin (75-100 mg daily)
nd either clopidogrel (75mg daily) or ticlopidine (250mg
wice a day) for at least 3 consecutive days, or (2) a loading
ose of 300 to 600 mg of clopidogrel or 500 mg of
iclopidine. Vascular access was achieved via the contralat-
ral (crossover) or ipsilateral (antegrade) approach at the
perators’ discretion. Following diagnostic arteriography
nd systemic anticoagulation, lesions were traversed using
ires and techniques most familiar to the operator. Suc-
Fig 1. The Dynalink-E self-expanding everolimus-eluting stent.essful wire traversal was an entry criterion for the study;
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August 2011396 Lammer et alpredilation prior to stent placement was allowed but not
mandatory.
The drug-eluting stent was available in lengths of 28,
80, and 100 mm, with diameters of either 6 or 8 mm. The
maximum allowable stent length per patient was 200 mm.
Postdilation was mandatory to optimize stent strut apposi-
tion. Completion fluorography or a biplane X-ray was
performed postdeployment to serve as a baseline for stent
integrity evaluation at 12 months. Postprocedure, patients
received a minimum daily dose of 75 mg of aspirin and
either clopidogrel 75 mg or ticlopidine 250 mg daily for at
least 6 months.
Follow-up patient visits, including duplex ultrasound
examinations were performed at 1, 6, and 12 months.
Clinical assessments included routine history and physical
examination, as well as completion of Walking Impairment
Questionnaires (WIQ).22 Duplex examinations were aided
by the use of a flexible centimeter tape affixed to the patient.
Peak systolic velocity (PSV) measurements were obtained
from a minimum of eight standard locations in the target
vessel; in cases of stents exceeding 8 cm length, PSV mea-
surements were obtained at 2-cm intervals. Duplex criteria
used to determine the presence of an in-stent50% steno-
sis included an increase of the intrastenotic PSV of 150% in
reference to the proximal prestenotic PSV from the same
vessel segment (PSV ratio 2.5). An independent core
laboratory reviewed and verified the data by comparing the
site-reported data with the actual recorded PSV measure-
ments (Bioclinica BV, Leiden, The Netherlands). Fol-
low-up diagnostic angiography was performed after 12
months using a standardized protocol and analyzed by an
independent core laboratory (BioImaging Technologies,
Leiden, The Netherlands). Follow-up plain radiography
was performed after 12 months for the purposes of evalu-
ating stent integrity. X-rays were obtained under two dif-
ferent projections separated by at least 45° using the high-
est available magnification then analyzed for strut fracture
by an independent core laboratory (Bioclinica).
Endpoints, data collection, and statistical analysis.
The primary endpoint of the STRIDES trial was the rate of
in-stent binary restenosis (50% stenosis using duplex ve-
locity criteria) at 6 months. Secondary endpoints included
acute device success, change in Rutherford-Becker clinical
category, improvement in walking capacity by WIQ, and
rates of stent fracture, primary patency, target lesion revas-
cularization, limb salvage, and survival after 12 months.
Failure of primary patency was defined as the presence of
50% restenosis by duplex or angiogram, or at the first
occurrence of one of the following: reintervention for the
purpose of treating the target lesion, total occlusion of the
target lesion, surgical bypass of the target lesion, or ampu-
tation of the extremity due to target lesion restenosis or
occlusion.
Data were collected on electronic case report forms
(InForm; PhaseFoward, Waltham, Mass) and adjudication
for prespecified study endpoints was provided by an inde-
pendent Clinical Events Committee (Harvard Clinical Re-
search Institute, Boston, Mass). An independent Data wafety Monitoring Board reviewed the study at prespecified
ntervals (coordinated by Harvard Clinical Research Insti-
ute, Boston, Mass).
All patients that received study stents were included in
he analysis (intent-to-treat). Endpoint values are summa-
ized descriptively at baseline and at follow-up with mean,
edian, or percentage. Primary patency, freedom from
arget lesion revascularization (TLR), and limb salvage
ates are reported using Kaplan-Meier methods according
o recommendations by the Society for Vascular Surgery Ad
oc Committee for reports dealing with lower extremity
schemia23 as well as the DEFINE Group’s recommenda-
ion for reporting of clinical endpoints in peripheral endo-
ascular revascularization trials.24 The protocol-defined
imewindows for clinical and radiographic evaluations were
14 days for 6-month evaluations and 28 days for 12-
onth evaluations.
ESULTS
One hundred four patients (with 106 lesions) were
nrolled at 11 European investigative centers betweenMay
007 and January 2008. The patients’ clinical and lesional
emographics are given in Table I. As expected, the popu-
ation had severe disease, including a significant proportion
f patients with coronary artery disease (42%), diabetes
ellitus (39%), and critical limb ischemia (17%).
Lesional demographics are given in Table II. The target
esions were complex, including a mean lesion length of
.0  4.3 cm, with significant proportions of Trans-
tlantic Inter-Society Consensus (2000) C lesions (78%),
otal occlusions (45%), lesions10 cm (39%), and resteno-
es (9.4%).
Details of the 104 interventional procedures are given
n Table III. Predilation of lesions prior to stent placement
able I. Clinical demographics of 104 patients enrolled
n the STRIDES trial
Mean  SD or %
ge (years) 69  8.9
ale gender 57%
urrent smoker 37%
iabetes mellitus 39%
ypertension 78%
ypercholesterolemia 57%
oronary artery disease 42%
erebrovascular disease 18%
rior ipsilateral lower extremity intervention 19%
ontralateral peripheral vascular disease 60%
utherford-Becker classification
II (moderate claudication) 34%
III (severe claudication) 49%
IV (ischemic rest pain) 8.7%
V (ulceration) 8.7%
imb salvage indication (CLI) 17%
aseline ankle-brachial index 0.64  0.19
LI, Critical limb ischemia; STRIDES, Superficial Femoral Artery Treat-
ent with Drug-Eluting Stents.as optional and was performed in 63% of cases. Postdila-
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Volume 54, Number 2 Lammer et al 397tion was required to ensure optimal stent expansion and
apposition; it was performed for 98% of stented lesions. The
majority of patients had either one (58%) or two (36%)
stents implanted.
All patients were treated with either clopidogrel or
ticlopidine prior to the procedure as specified in the proto-
col; 83% of patients received continuous thienopyridine
treatment through the first 6 months. Thienopyridine
treatment beyond 6months was left to the discretion of the
treating physician; at the end of 12 months, 61% of patients
remained on therapy. Low-dose aspirin therapy (75-100
Table II. Demographics of the 106 lesions treated in the
STRIDES trial
Mean  SD or %
Lesion origin
De novo 91%
Restenotic 9.4%
Calcification
Moderate 51%
Severe 27%
Reference vessel diameter (mm) 5.3  0.6
Lesion length (cm) 9.0  4.3
Total occlusion (%) 45%
TASC (2000) lesion classification
A 5%
B 17%
C 78%
D 0%
TASC (2007) lesion classification
A 42%
B 45%
C 13%
D 0%
Patent crural outflow vessels
One 26%
Two 27%
Three 47%
STRIDES, Superficial Femoral Artery Treatment with Drug-Eluting Stents;
TASC, Trans-Atlantic Inter-Society Consensus.
Table III. Procedural details of 104 endovascular
interventions in the STRIDES trial
Mean  SD or %
Predilation
% of cases 63%
Maximum balloon pressure (atm) 9.2  2.3
Postdilation
% of cases 98%
Maximum balloon pressure (atm) 10.3  2.6
Number of stents implanted per patient
One 58%
Two 36%
Three or more 6.7%
Device success (per device), % 98%
Procedure duration, median min (range) 53 (35-820)
Hospital stay, median days (range) 2 (1-35)
STRIDES, Superficial Femoral Artery Treatment with Drug-Eluting Stents.mg per day) was continuously maintained in 87% of pa- dients during the first 6 months; at the end of 12 months,
2% were taking aspirin.
Ninety-eight patients (94%) underwent duplex imag-
ng at 6 months for assessment of in-stent restenosis, the
rial’s primary endpoint. The rate of restenosis at 6 months
as 14% (95% confidence interval, 7.8%-22.2%).
Patient follow-up at 12 months was 99%. Mean resting
nkle-brachial index (ABI) increased from a preprocedure
evel of 0.64  0.19 to 0.92  0.16 postprocedure, then
emained elevated at 0.98 0.14, 0.91 0.17, and 0.89
.20 at 1, 6, and 12 months, respectively.
Clinical results as assessed by Rutherford-Becker clini-
al category andWalkingDistance are given in Figs 2 and 3,
espectively. There was sustained clinical benefit in the
ajority of patients, with improvements in Rutherford-
ecker clinical category observed in 80% after 12 months.
ndovascular intervention afforded significant improve-
ents in ambulation such that the percentage of patients
hat could ambulate 1500= (457 m) increased from 1%
reprocedure to 53%, 51% and 43% at 1, 6, and 12 months,
espectively.
Observed rates of primary patency (freedom from re-
tenosis) and freedom from TLR by Kaplan-Meier analysis
re shown in Fig 4. Note that the abscissa extends to 393
ig 2. Clinical results of the Superficial Femoral Artery Treat-
ent with Drug-Eluting Stents (STRIDES) trial as assessed by
utherford-Becker clinical category (RB). The number of patients
valuated at each interval is shown in parentheses.
ig 3. Improvement in ambulation following endovascular inter-
ention in the Superficial Femoral Artery Treatment with Drug-
luting Stents (STRIDES) trial. Patients’ ability to ambulate was
easured at prespecified time intervals by the Walking Improve-
ent Questionnaire (WIQ). The figure shows, at each interval of
tudy, the percentage of patients that were able to ambulate the
tated distances.ays to account for the 28-day window around the 365-day
TA
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RIDES) trial.
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August 2011398 Lammer et alendpoint. Freedom from TLR after 6 and 12 months was
95  2.1% and 80  3.8%, respectively. Primary patency
after 6 and 12 months was 94  2.3% and 68  4.6%,
respectively.
There was no limb loss in claudicants (100% limb
salvage in 86 patients). The 12-month rate of limb salvage
in patients with critical limb ischemia was 89 7% (16/18
patients with salvaged limbs). The first case of ipsilateral
major amputation occurred in a 78-year-old woman with
tissue loss in the left foot (Rutherford-Becker 5) and an ABI
of 0.21. Following uneventful stent placement, her course
was complicated by heparin-induced thrombocytopenia
and thrombosis requiring below-knee amputation 12 days
following the procedure. The second case was that of an
83-year-old female with congestive cardiomyopathy and
prior revascularization of the left leg who presented with
ischemic tissue loss in the right foot and underwent un-
eventful stent placement in the distal right SFA. Unfortu-
nately, her course was complicated by recurrent pneumo-
nia, gastrointestinal bleeding requiring colectomy, and
poor wound healing eventually requiring below-the-knee
amputation after multiple toe and transmetatarsal amputa-
tions failed to heal. She succumbed to multisystem organ
failure 10 months following the procedure. Other serious
Fig 4. Freedom from target lesion revascularization (so
Femoral Artery Treatment with Drug-Eluting Stents (STadverse events (SAEs) are given in Table IV.
S
mable IV. SAEs in the STRIDES trial
N (%)
ccess site
Hematoma 1 (1.0%)
Pseudoaneurysm 2 (1.9%)
on-access site bleeding
Hematoma 1 (1.0%)
Other 1 (1.0%)
ardiac/hemodynamic
Angina 4 (3.9%)
Congestive cardiomyopathy 2 (1.9%)
Other 8 (7.7%)
ulmonary
Pneumonia 5 (4.8%)
Pulmonary edema 2 (1.9%)
Pulmonary embolism 1 (1.0%)
Other 3 (2.9%)
troke 1 (1.0%)
arcinoma 6 (5.8%)
astrointestinal 3 (2.9%)
nfectious 4 (3.8%)
iscellaneous
Back pain 1 (1.0%)
Fever 1 (1.0%)
Peripheral neuropathy 1 (1.0%)
Joint pain 1 (1.0%)lid line) and primary patency (dashed line) in the SuperficialAEs, Serious adverse events; STRIDES, Superficial Femoral Artery Treat-
ent with Drug-Eluting Stent.
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Volume 54, Number 2 Lammer et al 399Stent integrity was examined radiographically after 12
months in 122 devices. There was no evidence for strut
fracture in any device.
DISCUSSION
As significant enhancements in stented arterial patency
have been achieved in the coronary circulation through the
use of DES,6 it was inevitable that this technology would
eventually be applied to the peripheral circulation. Several
small series have been published that suggest that drug-
eluting stents designed for the coronary arteries might also
be efficacious in limiting restenosis and improving patency
in the infrapopliteal arteries.9 Similarly, the hypothesis that
drug-eluting stents might also be efficacious in the larger
and more complex SFA was first addressed by the SI-
ROCCO (SIROlimus Coated Cordis SMARTNitinol Self-
expandable Stent for the Treatment of Obstructive Super-
ficial Femoral Artery Disease) studies, which were
published in 2002 and 2005.7,8,10 The SIROCCO self-
expanding drug-eluting stent (Cordis, a Johnson and John-
son Company, Miami Lakes, Fla) utilized the nitinol
SMART (Shape Memory Alloy Recoverable Technology)
stent as its platform, was loaded with 90-g sirolimus/cm2
stent area using a 5- to 10-m copolymer matrix (total
drug load 1 mg per 80-mm stent) and delivered its drug
load over a period of about 7 days.8 A total of 93 patients
were enrolled in the combined SIROCCO I and SI-
ROCCO II clinical trials. Unfortunately, neither trial
achieved a significant reduction in restenosis and, even after
4 years, there was no difference in any metric comparing
patients treated with the bare SMART stent vs the siroli-
mus-eluting SIROCCO stent.10
In retrospect, some have hypothesized that the failure
of the SIROCCO stent design was in its inadequate drug
delivery. As stated, the SIROCCO stent was loaded with
90-g sirolimus/cm2 stent area, which was considerably
lower than the successful sirolimus-eluting coronary stent
(Cypher [Cordis], 140 g sirolimus/cm2 stent area).20
Moreover, the SIROCCO stent released sirolimus over
about 7 days, considerably more rapidly than the 30-day
release profile of the Cypher stent. Lastly, an unexpected
finding in the SIROCCO trial and a possible reason for its
failure, was the observation that the stent platform was
prone to fracture. Of the 93 patients enrolled, stent fracture
was found in 18% at 6 months, including single strut
fractures in eight patients, multiple strut fractures in four
patients, complete transverse linear stent separations in two
patients, and transverse linear fractures with stent displace-
ment in two patients.25 It has been suggested that stent
fracture may create a nidus for restenosis, given the docu-
mented association between strut fracture, restenosis, and
therapeutic failure.26 Indeed, the reported frequency of
strut fracture following peripheral stenting is surprisingly
high,11,27 including one retrospective clinical study dem-
onstrating a fracture rate of 65%.28
The everolimus-eluting self-expanding nitinol stent
utilized in the STRIDES trial was designed to address and
potentially overcome these shortcomings of prior periph- dral DES by providing (1) a higher level of drug delivery
o the target tissue, (2) a longer profile of elution leading to
ustained suppression of proliferation, and (3) resistance to
tent fatigue and fracture due to its flexible design. The
verolimus-eluting self-expanding stent was loaded with
elatively high overall drug content (225 g everolimus/
m2 stent area) compared with coronary stents that elute its
nalogs (eg, Xience V [Abbott] 100 g everolimus/cm2,
ypher 140 g sirolimus/cm2, Endeavor [Medtronic,
inneapolis, Minn] 160 g zotarolimus/cm2). The
ose of 225 g everolimus/cm2 stent area was chosen as
his roughly corresponds to a twofold increase in dose/
m2 arterial area compared with coronary DES formula-
ions. Equally important as the total bulk dose is its release
rofile. Using an ethylene vinyl alcohol copolymer system,
he everolimus-eluting peripheral DES was designed to
elease drug over a period of approximately 3 months,
ompared with coronary DES, which release drug over only
bout 30 days. The comparatively prolonged release rate of
he everolimus-eluting peripheral DES was intended to
oughly match the kinetics of nitinol stent expansion, as
versized self-expanding nitinol stents continue to enlarge
o their nominal diameter and potentially remodel the
uman arterial wall for at least 6 months.29
The Dynalink/Absolute stent platform utilized in the
resent study has previously been shown to resist fracture
hen implanted in the SFA. For example, in a comparative
etrospective study of three different peripheral stents, ra-
iographic strut fracture within the Dynalink/Absolute
Abbott Laboratories) stent was observed in only 1.8% of
ases after a mean follow-up of 15  9 months, while
ractures of SMART (Cordis) and Wallstents (Boston Sci-
ntific, Natick, Mass) were observed in 28% and 19% of
ases, respectively (mean follow-up of 32 16 months and
3  24 months, respectively).11 Similarly, in a random-
zed, prospective, single-center study of percutaneous
ransluminal angioplasty (PTA) alone vs PTA with Abso-
ute stent placement, stent fracture was observed in only
% of patients.4,12 Taken together, the results of these
tudies suggest that the Dynalink/Absolute nitinol stent
attern is well-suited to the environment of the SFA and
hat chronic implantation is not associated with high
ates of fracture.
Thusly designed, clinical testing of the everolimus-
luting peripheral DES was undertaken in the STRIDES
rial. In STRIDES, successful device placement was
chieved in 98% of cases, and 99% of patients were available
or 12-month follow-up, which included repeat duplex
maging in 90% and arteriography in 83%. Clinical improve-
ent (sustained decrease in Rutherford-Becker clinical
ategory) was achieved in 80% of patients. Primary pa-
ency (freedom from50% in-stent restenosis) was 94
.3% and 68  4.6% at 6 and 12 months, respectively,
nd plain radiographic examination of 122 implanted
evices revealed no evidence for stent fracture. Clearly,
he results of this initial clinical trial suggest that this
evice is safe and effective for the treatment of this
isease.
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peripheral DES tested in the STRIDES trial appeared to be
far less effective at preventing restenosis than typical coro-
nary DES. Each of the Cypher, Taxus (Boston Scientific),
and Endeavor coronary DES have been shown to have
profound effects on coronary neointimal hyperplasia, re-
ducing restenosis from 24%-35% to 3.2%-9.4% in pivotal
clinical trials.20,30,31 In contrast, the 68  5% patency rate
observed in the current trial appears to be only a modest
improvement in outcome compared with historical results.
For example, in a cohort of 51 patients with similar demo-
graphics and lesion characteristics treated with the bare
metal Dynalink/Absolute stent, a 12-month primary pa-
tency rate of 63 7% was observed.4,12 Similarly, although
lesion complexity and reporting methods vary widely, con-
temporary reports of patency rates using other bare nitinol
or covered stents in the current era range from 50% to
81%.2-5,32-35 Given these results, it is difficult to conclude
that the everolimus-eluting peripheral DES represents a
significant advance in currently available interventional
technology.
The results of the STRIDES trial are also noteworthy
given the large number of restenotic events that were
observed during months 7 to 12. As seen in Fig 4, the
favorable primary patency rate of 94% that was observed at
6 months had decreased to a disappointing 68% by 1 year.
Interestingly, this phenomenon was also observed in the
SIROCCO trial wherein the impressive 5% restenosis rate
noted at 6 months had increased to 19% at 18 months,
which was no different than bare nitinol controls.7,8,10 This
suggests, perhaps, that neither DES was formulated with a
long enough elution profile to overcome the continued
interaction between stent and SFA.
In conclusion, the everolimus-eluting self-expanding
nitinol stent can be safely and successfully implanted in
patients with severe PAD, with favorable outcomes and
clinical improvements observed in the majority of patients.
Neointimal hyperplasia appeared to be inhibited and pa-
tency enhanced during the first 6 months. The effect was
not sustained, however, as primary patency had decreased
to 68% by 12 months.
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